Chemical forms of selenium for cancer prevention

被引:160
作者
Abdulah, R [1 ]
Miyazaki, K [1 ]
Nakazawa, M [1 ]
Koyama, H [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Publ Hlth, Maebashi, Gumma 3718511, Japan
关键词
selenium; selenoproteins; monomethylated selenium; cancer; HPLC-ICP-MS;
D O I
10.1016/j.jtemb.2005.09.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Cancer is becoming an increasingly significant disease worldwide. Currently, more than 7 million people die each year from cancer. With the existing knowledge, at least one-third of worldwide cancer cases could be prevented. Searching for naturally occurring agents in routinely consumed foods that may inhibit cancer development, although challenging, constitutes a valuable and plausible approach to the control and prevention of cancer. To date, the use of the micronutrient selenium (Se) in human clinical trials is limited, but the outcome indicates that Se is among the most promising agents. Although it is convenient to describe the effects of Se in terms of the element, it must always be kept in mind that the chemical form of Se and the dose are determinants of its biological activities. Hyphenated techniques based on coupling chromatographic separation with inductively coupled plasma mass spectrometric (ICP-MS) detection are now established as the most realistic and potent analytical tools available for real-life speciation analysis. These speciation investigations provide evidence that the Se compounds, which can generate monomethylated Se (e.g., Se-methylselenocysteine and methylseleninic acid), are more efficacious than other Se compounds because of their chemoprevention activity. (c) 2005 Elsevier GmbH. All rights reserved.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 91 条
[1]
Binding of selenoprotein P to heparin: Characterization with surface plasmon resonance [J].
Arteel, GE ;
Franken, S ;
Kappler, J ;
Sies, H .
BIOLOGICAL CHEMISTRY, 2000, 381 (03) :265-268
[2]
Arteel GE, 1998, BIOL CHEM, V379, P1201
[3]
Thyroid function [J].
Arthur, JR ;
Beckett, GJ .
BRITISH MEDICAL BULLETIN, 1999, 55 (03) :658-668
[4]
Separation and identification of Se-methylselenogalactosamine -: a new metabolite in basal human urine -: by HPLC-ICP-MS and CE-nano-ESI-(MS)2 [J].
Bendahl, L ;
Gammelgaard, B .
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2004, 19 (08) :950-957
[5]
SELENOCYSTEINE - THE 21ST AMINO-ACID [J].
BOCK, A ;
FORCHHAMMER, K ;
HEIDER, J ;
LEINFELDER, W ;
SAWERS, G ;
VEPREK, B ;
ZINONI, F .
MOLECULAR MICROBIOLOGY, 1991, 5 (03) :515-520
[6]
MOLECULAR-BIOLOGY OF SELENIUM WITH IMPLICATIONS FOR ITS METABOLISM [J].
BURK, RF .
FASEB JOURNAL, 1991, 5 (09) :2274-2279
[7]
Burk RF, 2003, J NUTR, V133, p1517S, DOI 10.1093/jn/133.5.1517S
[8]
Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo [J].
Caffrey, PB ;
Frenkel, GD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (01) :74-78
[9]
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts [J].
Cao, SS ;
Durrani, A ;
Rustum, YM .
CLINICAL CANCER RESEARCH, 2004, 10 (07) :2561-2569
[10]
Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial [J].
Clark, LC ;
Combs, GF ;
Turnbull, BW ;
Slate, EH ;
Chalker, DK ;
Chow, J ;
Davis, LS ;
Glover, RA ;
Graham, GF ;
Gross, EG ;
Krongrad, A ;
Lesher, JL ;
Park, HK ;
Sanders, BB ;
Smith, CL ;
Taylor, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24) :1957-1963